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Background: A novel chromogenic medium for isolation and identification of Pseudomonas aeruginosa from sputa of cystic fibrosis (CF) patients
was evaluated and compared with standard laboratory methods.
Methods: One hundred sputum samples from distinct CF patients were cultured onto blood agar (BA), Pseudomonas CN selective agar (CN) and a
Pseudomonas chromogenic medium (PS-ID). All Gram-negative morphological variants from each medium were subjected to antimicrobial
susceptibility testing, and identification using a combination of biochemical and molecular methods.
Results: P. aeruginosa was isolated from 62 samples after 72 h incubation. Blood agar recovered P. aeruginosa from 56 samples (90.3%)
compared with 59 samples (95.2%) using either CN or PS-ID. The positive predictive value of PS-ID (98.3%) was significantly higher than
growth on CN (88.5%) for identification of P. aeruginosa (Pb0.05).
Conclusions: PS-ID is a promising medium allowing for the isolation and simultaneous identification of P. aeruginosa from sputa of CF patients.
Crown Copyright © 2008 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. All rights reserved.Keywords: Pseudomonas aeruginosa; Culture media; Enzyme substrates; Cystic fibrosis; Respiratory infection1. Introduction
Pseudomonas aeruginosa is the most common and impor-
tant species colonising the lungs of cystic fibrosis patients
contributing to an accelerated decline in lung function.
Colonisation rates are estimated at 80% in adults and 60% in
the CF population overall [1]. Once P. aeruginosa is established
in the lung it is extremely difficult to eradicate [2]. Early
detection of P. aeruginosa, before its conversion to a mucoid
phenotype, and aggressive early treatment with appropriate
antimicrobials, has been advocated to limit the severity of
infection [3].
Detection of P. aeruginosa colonisation is normally achieved
by culture of sputum or laryngeal secretions onto artificial
media. Typical isolation media for respiratory pathogens⁎ Corresponding author. Tel.:+44 191 2231226; fax: +44 191 2231224.
E-mail address: john.perry@nuth.nhs.uk (J.D. Perry).
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doi:10.1016/j.jcf.2008.11.003include blood agar and chocolate agar as well as selective
agars such as MacConkey agar and cetrimide-based media.
Despite the large amounts of P. aeruginosa often present in the
sputa of colonised patients, isolation and identification may
often be challenging to microbiology laboratories. P. aerugi-
nosa from CF sputa often have an atypical appearance and
present as mucoid phenotypes and small colony variants.
Production of pyocyanin, a blue-green pigment typically
produced by P. aeruginosa, is also frequently absent [4].
Specialised selective agars containing a detergent, cetrimide,
have been recommended to facilitate isolation, however these
have limited ability to differentiate P. aeruginosa from the
polymicrobial flora often present in CF sputa. Other species
of Pseudomonas as well as Stenotrophomonas maltophilia,
Achromobacter xylosoxidans and Ralstonia pickettii have
been shown to grow on the cetrimide-based media [5] and
may be indistinguishable from non-pigmented strains of P.
aeruginosa..V. on behalf of European Cystic Fibrosis Society. All rights reserved.
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difficulties in biochemical identification. Biochemical test kits
such as API 20 NE are commonly used for identification [6],
however a high rate of misidentification of oxidase positive
Gram-negative rods including P. aeruginosa has been demon-
strated using this system [7]. In addition, the test requires the
use of a pure bacterial subculture and a minimum incubation
time of 48 h. Hence, identification using this method requires at
least 3 days.
We evaluated the potential of a novel chromogenic medium
for the isolation and simultaneous identification of P. aerugi-
nosa. As well as including selective agents for the inhibition of
many other species, the medium contains a chromogenic
substrate for ß-alanyl aminopeptidase, which is hydrolysed by
P. aeruginosa resulting in the formation of purple colonies
[8]. The aim of this study was to evaluate a novel prototype
chromogenic agar medium (PS-ID), for the isolation and
identification of P. aeruginosa from CF sputum samples and
to compare its performance to routine media used in the
laboratory.
2. Materials and methods
2.1. Materials
Columbia agar (CM0331) and Isosensitest agar (CM0471)
were prepared from dehydrated powders in accordance with
manufacturer's instructions (Oxoid, Basingstoke, UK). Molten
Columbia agar at 50 °C was supplemented with 5% defibrinated
horse blood (TCS Biosciences Ltd., Buckingham, UK) and
plates were prepared. Pseudomonas CN selective agar
(PO0185A) was obtained as pre-poured plates from Oxoid,
Basingstoke, UK. The Pseudomonas chromogenic medium
(PS-ID) was provided as pre-poured plates by bioMérieux, La
Balme-les-Grottes, France, for research purposes only. Phenan-
throline/C-390 agar containing 1,10-phenanthroline (Sigma
Chemical Company, Poole, UK) and C-390 (Biosynth AG,
Switzerland) was prepared as previously described [9].
Cetrimide agar and API 20 NE strips were obtained from
bioMérieux, Basingstoke, UK. Amikacin, gentamicin, tobra-
mycin, ciprofloxacin, aztreonam, piperacillin/tazobactam, ticar-
cillin/potassium clavulanate and ceftazidime were obtained
from Sigma Chemical Company, Poole, UK as powders of
known potency. Temocillin and meropenem were obtained from
their respective manufacturers.
2.2. Culture of sputum samples
One hundred sputum samples were collected from distinct
cystic fibrosis patients (mean age: 26 years, range 4–62 years),
who visited the cystic fibrosis clinic at the Royal Victoria
Infirmary, Newcastle upon Tyne or were attending the Freeman
Hospital for lung transplant assessment. The sputum was
homogenised with an equal amount of sputasol by vigorously
shaking the sample on a vortex mixer at room temperature for
30 min. A 1/1000 dilution of the sputum was obtained by
adding 10 µL of the homogenised sputum into 9.99 mL ofsterile distilled water. A 10 µL aliquot of both the undiluted and
diluted sputum were separately plated onto Columbia blood
agar (BA), Pseudomonas CN selective agar (CN) and PS-ID.
The media were incubated aerobically at 37 °C for a total of
72 h and were read after each 24 h interval. Any presumptive
Gram-negative isolate, including all morphological variants,
from the three media were sub-cultured by touching a single
colony with a sterile wire and inoculating a BA plate. Colonial
appearance including size, shape and colour of colonies on the
three primary isolation media was recorded. Sub-cultured
colonies were subjected to Gram stain and storage at −20 °C
in glycerol for later use.
2.3. Phenotypic identification
A 10 μL aliquot of each stored isolate along with the positive
control strain P. aeruginosa (NCTC 10662) and the negative
control E. coli (NCTC 10418) were sub-cultured onto BA and
grown overnight. Standardized suspensions were prepared in
water to a density equivalent to a 0.5 McFarland standard
(approximately 1.5×108 cfu/mL) using a densitometer. A 1 µL
aliquot of each suspension was inoculated onto BA, Phenanthro-
line/C-390 agar and cetrimide agar using a multipoint inoculator.
All plates were incubated at 37 °C and a duplicate set of blood
agar plates was inoculated and incubated at 42 °C. All media were
incubated for 48 h after which growthwas recorded. Oxidase tests
were performed from growth on BA at 37 °C. Isolates were
confirmed to be P. aeruginosa if they were oxidase positive, grew
on Phenanthroline/C-390 agar and cetrimide agar and also grew
on BA at 42 °C (Fig. 1). Any oxidase negative isolates were
identified using API 20NE. Any oxidase positive isolates that did
not confirm as P. aeruginosa using the above method were
subjected to species specific multiplex PCR (see 2.4) and any
isolates not confirmed as P. aeruginosawere identified using API
20 NE. All isolates of confirmed P. aeruginosa (from any
medium) were inoculated onto PS-ID as described above.
Of the Gram positive organisms, Staphylococcus aureus
isolates were confirmed by latex agglutination test (Slidex
Staph Plus) and the other organisms were presumptively
identified by Gram-stain and a catalase test. Yeasts and
filamentous fungi were confirmed by microscopy and atypical
mycobacteria with an acid fast stain.
2.4. Species-specific PCR
In preparation for the species-specific multiplex PCR the
appropriate stored isolates were inoculated onto BA and
incubated overnight. DNA extraction was carried out by
preparing a 1 mL light suspension of each organism in PCR
grade water and centrifuging this for 5 min at 13,000 rpm. The
supernatant was decanted and the pellet was re-suspended in
100 μL of a 5%, w/v Chelex suspension [10]. The mixture was
then boiled for 5 min at 100 °C and subsequently frozen at -20 °C
for 5 min. This freeze thaw step was repeated once after which the
mixture was centrifuged again at 13,000 rpm for 5 min. The
supernatant containing the extracted DNAwas transferred into a
new centrifuge tube.
Fig. 1. Algorithm for identification of Gram-negative isolates. (PC: Phenanthroline/C-390 agar).
Fig. 2. Morphological variation of P. aeruginosa isolates growing on PS-ID
from culture of a CF sputum sample.
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described method [11]. The primers used were P. aeruginosa
algD gene specific primers VIC1 and VIC2 and universal
bacterial 16 S primers 11E and 13B. Various control strains
were tested in each batch of tests including P. aeruginosa
(NCTC 10662), Pseudomonas fluorescens (NCTC 10688),
Pseudomonas putida (NCTC 10475), Pseuudomonas putida
(NCTC 10936), S. maltophilia (NCTC 10257) and Burkhol-
deria cenocepacia (LMG 16656).
2.5. Antimicrobial susceptibility testing
Stored isolates were inoculated onto BA and incubated
overnight. The ten antimicrobials listed above (see 2.1) were
incorporated into Isosensitest agar at breakpoint concentrations
used to define resistance (see Table 2) and inoculated with 10
000 cfu/spot of each confirmed isolate of P. aeruginosa using a
multipoint inoculator. P. aeruginosa (NCTC 10662) and
Escherichia coli (NCTC 10418) were included as controls of
known susceptibility. Procedures and interpretation of anti-
microbial susceptibility were performed in strict accordance
with the recommendations of the British Society for Anti-
microbial Chemotherapy [12]. Susceptibility to temocillin was
interpreted using a breakpoint of 8 mg/L as previously
recommended [13].
2.6. Statistical methods
The positive predictive value (PPV), negative predictive
value (NPV) and sensitivity were calculated for the capability of
each medium to isolate P. aeruginosa. The difference between
sensitivity and specificity values for the media was assessed
using the χ2 test [14]. The difference between the mean number
of antibiograms and morphological variants obtained by the
different media was assessed by a two sample t test [14].
Differences between the number of samples with resistant P.
aeruginosa isolates detected by the three different media were
assessed using McNemar's test [14]. In all cases, a significant
difference was defined as a P value of b0.05.3. Results
3.1. Isolation of P. aeruginosa
Morphological ‘variants’ were defined as isolates that could
be distinguished from other colonies on the grounds of colour,
size, shape or texture. Identical variants isolated from the same
sample from culture of both ‘neat’ and diluted sputum were
counted as a single variant. Using a combination of cultures
from both ‘neat’ and diluted sputum, 479 Gram-negative
morphological variants isolated from all three media were
stored for identification. Of these, 408 oxidase positive isolates
were proven to be Pseudomonas aeruginosa using either,
growth on Phenanthroline/C-390 agar and cetrimide agar and
growth at 42 °C (362 isolates) or species-specific PCR (46
isolates). Using a combination of the three isolation media, P.
aeruginosa was isolated from 62 of the 100 samples. Other
Gram-negative bacteria that were recovered included A.
xylosoxidans (from nine samples), S. maltophilia (from eight
samples), Burkholderia cepacia complex (from three samples),
P. fluorescens (from two samples) and R. pickettii (from one
Table 1
Comparison of three media for the detection of P. aeruginosa in sputa from
patients with CF
24 h 48 h 72 h
No. of positive samples
BA 46 55 56
CN 52 59 59
PS-ID 36 58 59
Sensitivity (%)
BA 74.1 88.7 90.3
CN 83.9 95.2 95.2
PS-ID 58.1 93.5 95.2
PPV (%)
BA N/A N/A N/A
CN 89.7 88.5 88.5
PS-ID 100 98.3 98.3
NPV (%)
BA N/A N/A N/A
CN 76.2 90.9 90.9
PS-ID 59.4 90.2 92.5
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positive pathogens and fungi e.g. 19 samples grew S. aureus of
which five were methicillin resistant, 11 samples grew yeast, six
grew filamentous fungi and two samples yielded mycobacteria.
P. aeruginosa typically formed purple colonies on PS-ID but
some isolates generated colonies that produced shades of pink
or red. Typical appearance of P. aeruginosa on PS-ID is shown
in Fig. 2. Any pink, red or purple colonies were regarded as
presumptive P. aeruginosa. A large majority of confirmed
isolates of P. aeruginosa did not produce pigment on CN andFig. 3. Three samples of CF sputa plated onto blood agar (A), CN (B) and PS-ID (C).
easily distinguishable. In sample 2, P. aeruginosa is also present but pigment is weak
sample 3). PS-ID provides distinction of both isolates of P. aeruginosa by their apptherefore, for the purposes of comparison, any Gram-negative
bacteria isolated on CN were also regarded as presumptive P.
aeruginosa. Table 1 shows the performance of the three media
for isolation of P. aeruginosa. Of 182 colonial variants of P.
aeruginosa isolated on PS-ID, 96.7% produced purple, pink or
red colonies with six isolates (3.3%) producing either orange or
transparent colonies, which were regarded as ‘undetected’.
Mucoid colony variants had an overall inferior colour
production than the non-mucoid types. For most isolates,
colour production required 48 h to develop and therefore
sensitivity of PS-ID was relatively poor (58.1%) after 24 h
incubation. All isolates of confirmed P. aeruginosa from all
three media showed growth when inoculated as pure cultures
onto PS-ID and all but two isolates produced coloured colonies.
Both of these were among the six ‘undetected’ isolates
originally recovered on PS-ID. These two isolates were non-
mucoid and produced a typical colony size and were assumed to
be genuinely deficient in ß-alanyl aminopeptidase activity.
3.2. Presumptive identification on culture media
After 24 h incubation, any colony displaying purple, pink or red
coloration on PS-ID was confirmed as P. aeruginosa. After
incubation for 48–72 h, of 179 colony variants showing
such coloration, 176 were confirmed as P. aeruginosa (PPV=
98.3%). Two isolates of B. cepacia complex and one isolate of
Pseudomonas fluorescens also produced a coloration charac-
teristic of P. aeruginosa. On CN, 130 colony variants were
recovered of which 115 proved to be P. aeruginosaSample 1 contains P. aeruginosa producing strong pigmentation on CN and it is
or absent on CN thus causing it to resemble other species (e.g. A. xylosoxidans in
earance as distinctive purple colonies.
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(n=11), P. fluorescens (n=2) and B. cepacia complex (n=2).
No Gram-positive bacteria or yeasts were recovered on CN but
occasional isolates were encountered that formed either white
or blue colonies on PS-ID.
3.3. Colonial variation and antimicrobial susceptibility
A total of 111 variants of P. aeruginosa were detected on
BA, 115 on CN and 176 on PS-ID. The 6 colourless variants
isolated on PS-ID were considered as false negative and
therefore not included among the variants detected on PS-ID.
The number of variants per positive sample ranged from 1–3 for
BA, 1–4 for CN and 1–7 for PS-ID. The differences between
the mean numbers of variants per sample for both PS-ID (2.83)
and BA (1.79) and PS-ID and CN (1.85) were statistically
significant (Pb0.001). All variants from all three media were
tested concomitantly for susceptibility to each of ten anti-
microbial agents on the same batch of media. A variant was
regarded as having a distinct antibiogram if its susceptibility
profile differed from other variants in the same sputum sample.
An average of 3.87 antibiograms per sample (range 1–9) was
obtained by testing variants isolated from a combination of the
three media. The mean of number of antibiograms obtained per
sample was 1.58 for isolates recovered on BA (range 1–3), 1.60
for CN (range 1–4) and 2.27 for PS-ID (range 1–6). The
differences between the mean antibiogram values for both PS-
ID and BA, and PS-ID and CN were statistically significant
(Pb0.001).
Table 2 shows the number of samples from which at least one
antimicrobial resistant P. aeruginosa variant was recovered. For
comparative purposes it is assumed that all antimicrobial
resistant isolates were detected by a combination of the three
media, although this cannot be proven. Compared to BA and
CN, PS-ID showed a superior recovery of variants resistant to
amikacin, gentamicin, ceftazidime, temocillin, piperacillin-
tazobactam and ticarcillin-clavulanic acid. Compared with BA
and PS-ID, CN recovered more variants resistant to ciproflox-
acin. The same number of variants resistant to either tobramycin
or aztreonam was recovered by CN and PS-ID. BA consistentlyTable 2
Number of sputum samples containing at least one antimicrobial resistant P.
aeruginosa isolate
Antimicrobials⁎ (breakpoint concentration in mg/l)
AMK GEN TOB ATM CAZ MEM TEM TZP TIM CIP
(16) (4) (4) (8) (8) (8) (8) (16) (64) (1)
Total (all media
types)
38 53 17 36 39 36 45 37 39 42
Blood agar 26 41 8 26 30 30 30 26 28 37
% 68.4 77.4 47.1 72.2 76.9 83.3 66.7 70.3 71.8 88.1
CN 25 39 11 29 30 28 33 27 28 39
% 65.8 73.6 64.7 80.6 76.9 77.8 73.3 73 71.8 92.9
PS-ID 33 45 11 29 31 30 36 30 29 38
% 86.8 84.9 64.7 80.6 79.5 83.3 80 81.1 74.4 90.5
⁎AMK, amikacin; GEN, gentamicin; TOB, tobramycin; ATM, aztreonam, CAZ,
ceftazidime;MEM,meropenem; TEM, temocillin; TZP, piperacillin-tazobactam;
TIM, ticarcillin-clavulanic acid; CIP, ciprofloxacin.recovered less resistant variants than the other two media, al-
though it was equivalent with PS-ID for isolation of meropenem
resistant isolates. These differences were not statistically
significant except for the higher number of amikacin-resistant
isolates recovered on PS-IDwhen comparedwith isolation onCN
(P=0.045).
4. Discussion
P. aeruginosa is recognized as the most important pathogen
affecting cystic fibrosis patients, yet media designed for the
selective isolation of this important pathogen and standard
biochemical kits commonly used for identification have limited
utility. Pseudomonas CN agar is recommended for the isolation of
P. aeruginosa and contains cetrimide and nalidixic acid as
selective agents and potassium and magnesium ions to enhance
pigment production. However, a number of reports have
demonstrated the absence of pigment in strains isolated from
patients with CF [4,15–17]. Other Gram-negative bacteria that
can tolerate cetrimide, such as A. xylosoxidans, Enterobacter
spp., S. maltophilia and other Pseudomonas spp. [5], may be
indistinguishable from non-pigmented P. aeruginosa (see Fig. 3).
This necessitates the use of biochemical tests for species
identification but this can also be problematic. For example,
one previous study reported 52 isolates of nontypical P.
aeruginosa isolated from CF patients, identified by 16 S
ribosomal DNA sequence typing, that were misidentified or
could not be identified using API 20 NE [7].
These problems have led a number of workers to examine
genotypic methods for identification of P. aeruginosa from CF
patients and several have been described. For example, 16 S
ribosomal DNA sequence typing has been reported to offer
100% sensitivity and specificity for identification of P.
aeruginosa [18]. Real-time PCR, which can achieve identifica-
tion in a matter of hours, has also been evaluated [19]. Of three
gene targets targeted, the best sensitivity (98.4%) and specificity
(98.9%) were found with detection of oprI [19]. These methods,
however, were carried out on pure cultures obtained from
primary culture, which means that at least 48 h had passed
before the test could be carried out. Accurate identification of P.
aeruginosa directly from sputum samples is potentially more
valuable. Direct testing of CF sputa has been performed by
targeting the oprL and ETA genes [20] and also by PCR
amplification the algD gene [11]. However, neither of these
methods obtained 100% specificity and sensitivity. Fluorescent
in situ hybridisation, a rapid, specific and relatively inexpensive
method, has been used to identify P. aeruginosa directly from
CF sputa with 100% specificity but only 90% sensitivity [21].
Media containing chromogenic enzyme substrates are useful
tools for clinical laboratories for the isolation and presumptive
identification of a range of pathogens [22]. This report is the
first to evaluate a chromogenic agar medium specifically
designed for detection of P. aeruginosa. In this study, PS-ID
had a comparable sensitivity to CN at 48–72 h incubation and
afforded presumptive identification of P. aeruginosa with high
predictive value (98.3%). Chromogenic media are typical-
ly more expensive than conventional agars, largely due to the
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by the requirement for fewer additional tests, thus savings
should be made on reagents and workload. In contrast, geno-
typic methods require specialised equipment and training,
which limit their suitability for routine use in many clinical
laboratories [7].
An interesting observation when using PS-ID is the high
number of colony variants obtained when compared to other
media. Production of exopolysaccharide capsular material
(alginate) is substantially reduced on PS-ID in contrast to
blood agar and CN where highly mucoid isolates may obscure
the presence of other morphological types. Differences in the
expression levels of ß-alanyl aminopeptidase may also
contribute to colour variation between colony types on the
chromogenic medium. The fact that more colony variants were
isolated on PS-ID and tested, inevitably led to the isolation of
more isolates with varying antibiograms and consequently the
detection of more antimicrobial resistance (Table 2). Foweraker
et al. [23] demonstrated that identical colonies frequently
showed different antibiograms, while two colonies with a
different morphology could also have the same antimicrobial
sensitivity pattern. It would therefore be erroneous to conclude
that PS-ID has a superior ability to detect antimicrobial-resistant
isolates, however this is worthy of further exploration. The
mucoid aspect of a colony may be regarded as significant and,
while such strains are recovered on PS-ID, the amount of
capsular material is reduced. Complementary blood-based
media used for the isolation of other pathogens (e.g. Haemo-
philus influenzae) may be useful alongside PS-ID for high-
lighting mucoid strains of P. aeruginosa.
In conclusion, PS-ID has shown good potential as a primary
isolation medium for P. aeruginosa from CF sputa. The purple
colonies produced by P. aeruginosa are easy to distinguish, and
reading the cultures is quick and straightforward. Colonies can
be reliably identified as P. aeruginosa based on colony colour
alone, with a predictive value of 98.3%, without the requirement
for further biochemical tests. This saves resources and allows
the early confirmation of this important pathogen.
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